Sunshine Biopharma (SBFM) 0.0300 $SBFM
Sunshine Biopharma Signs Agreement With Lonza to Manufacture Its Lead Anti-Cancer Compound, Adva-27a
Marketwire Canada - Wed Nov 19, 10:00PM CST
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today an agreement with Lonza, a leading development and manufacturing company, for the manufacture of its anti-cancer drug, Adva-27a. Lonza's expertise and experience in small molecule development and manufacturing of active pharmaceutical ingredients, was an ideal fit for Sunshine's Adva-27a. Lonza's manufacturing capacity ranges from gram quantities for process validation to kilogram amounts for clinical trials and ton quantities for commercialization. Manufacturing will begin at Lonza's Nansha, China facility with the remaining key steps to be conducted in Lonza's high containment cytotoxic facility in Visp, Switzerland.
Ebola Virus Infections Could Potentially Be Treated With Sunshine Biopharma's Lead Anticancer Compound, Adva-27a
ACCESSWIRE - Mon Nov 03, 4:00AM CST
Montreal, Quebec / ACCESSWIRE / November 3, 2014 / Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has conducted a scientific review of the mechanisms by which Ebola virus penetrates human cells and takes over their machinery to multiply rapidly and go on to infecting other cells leading to massive cell destruction and ultimately death in nearly 80% of the cases. The review found that the progression of Ebola virus infection is very similar to that of Influenza A virus, the causative agent that was responsible for the death of over 90 million people in the 1918 flu pandemic. In severe Influenza A virus infections, a condition associated with high mortality rate called haemophagocytic lymphohistiocytosis (HLH) is developed by the affected patient. HLH has previously been treated successfully with Etoposide which increased survivability from 50% to 90% (LANCET, Volume 367, Pages 870-873, March 2006). Etoposide is an anticancer drug that inhibits the activity Topoisomerase II, an essential enzyme found in hyperactive, rapidly growing cells such as cancer cells and HLH cells. Like Etoposide, Sunshine Biopharma's lead anticancer compound, Adva-27a, is a Topoisomerase II inhibitor however it has been shown to be more effective and less toxic than Etoposide (ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). The latter characteristics make Adva-27a superior to Etoposide for possible treatment of Ebola patients with already weakened state of health.
Sunshine Biopharma Retains Renmark Financial Communications to Provide Investor Relations
Marketwired - Tue Oct 14, 7:06AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, including its proprietary lead anticancer compound Adva-27a, today announced that it has retained the services of Renmark Financial Communications Inc. to handle its investor relations activities.
Sunshine Biopharma's Wholly Owned Canadian Subsidiary Completes the SOP's Required by Health Canada to Secure Drug Establishment License
Marketwire - Wed Oct 01, 7:02AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that its wholly owned Canadian subsidiary has completed the drafting of all of the Standard Operating Procedures (SOP's) required by Health Canada for the procurement of a Drug Establishment License (DEL). The completed SOP's comprise 18 binders and over 2,000 pages of documentation. It is necessary for Sunshine to have the DEL in place in order to become a fully integrated pharmaceutical company with proprietary (Adva-27a) and generic pharmaceutical products offering.
Sunshine Biopharma Negotiating With CRO's to Initiate Master Drug File for Adva-27a Anticancer Compound
Marketwire - Wed Sep 03, 7:03AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it is currently negotiating with several Contract Research Organizations (CRO's) with the intent to engage one of them for the purposes of initiating, compiling and managing a regulatory master drug file for Adva-27a, the Company's flagship anticancer compound. A master drug file contains all of the information that regulatory agencies require as part of the drug development and approval process. Such information includes preclinical data, GMP manufacturing process, large animal studies and human trials.
Sunshine Biopharma's Wholly Owned Canadian Subsidiary Engages Health Canada Specialized Consultants to Secure Pharmaceutical Establishment License
ACCESSWIRE - Thu Aug 21, 7:01AM CDT
Montreal, Quebec, Canada / ACCESSWIRE / August 21, 2014 / Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that its wholly owned Canadian subsidiary has engaged consultants specialized in Health Canada procedures and requirements to prepare the necessary documentations and applications for the procurement of a Pharmaceutical Establishment License. Such licensing must be in place before the Company is able to sign manufacturing and distribution contracts and accept purchase orders for the sale of pharmaceutical products.
Sunshine Biopharma's Wholly Owned Canadian Subsidiary Secures Dedicated Space to Commence Global Generic Pharmaceutical Operations
Marketwire - Mon Aug 11, 7:03AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that its wholly owned Canadian subsidiary has secured dedicated space in order to commence operations in the generic pharmaceuticals business as planned. Having a specifically dedicated space is required in order for the Company to be granted a Pharmaceutical Establishment and Export License by Health Canada. Once we secure our Establishment Licensed we will be in a position to sign manufacturing and distribution contracts for sale of generic pharmaceuticals in Canada and elsewhere around the globe. According to various estimates, the annual worldwide market for generic pharmaceuticals which Sunshine Biopharma's Canadian subsidiary is positioning itself to participate in is in excess of $100 billion.
Sunshine Biopharma Launches Sunshine Biopharma Canada Inc., a Wholly Owned Canadian Subsidiary in Anticipation of Signing Manufacturing and Commercialization Contracts in Canada
Marketwire - Tue Jul 29, 7:03AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has formed Sunshine Biopharma Canada Inc., a Canadian wholly owned subsidiary for the purposes of conducting pharmaceutical business in Canada and elsewhere around the globe. Sunshine Biopharma anticipates that Sunshine Biopharma Canada will soon sign manufacturing, marketing, sales and distribution contracts for various pharmaceutical and biomedical products. According to various estimates, the worldwide market for generic pharmaceuticals which Sunshine Biopharma Canada is positioning itself to participate in is in excess of $100 billion per year.
Jang Attributes Peaceful Council Elections to Security Arrangements
by Seriki Adinoyi - All Africa Global Media - Wed Feb 26, 1:34AM CST
Governor Jonah Jang of Plateau State has attributed the peaceful conduct of the local government area elections in the state to the adequate security measures put in place for the exercise.
Sunshine Biopharma Signs Agreement With Lonza to Manufacture Its Lead Anti-Cancer Compound, Adva-27a
Marketwire Canada - Wed Nov 19, 10:00PM CST
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today an agreement with Lonza, a leading development and manufacturing company, for the manufacture of its anti-cancer drug, Adva-27a. Lonza's expertise and experience in small molecule development and manufacturing of active pharmaceutical ingredients, was an ideal fit for Sunshine's Adva-27a. Lonza's manufacturing capacity ranges from gram quantities for process validation to kilogram amounts for clinical trials and ton quantities for commercialization. Manufacturing will begin at Lonza's Nansha, China facility with the remaining key steps to be conducted in Lonza's high containment cytotoxic facility in Visp, Switzerland.
Ebola Virus Infections Could Potentially Be Treated With Sunshine Biopharma's Lead Anticancer Compound, Adva-27a
ACCESSWIRE - Mon Nov 03, 4:00AM CST
Montreal, Quebec / ACCESSWIRE / November 3, 2014 / Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has conducted a scientific review of the mechanisms by which Ebola virus penetrates human cells and takes over their machinery to multiply rapidly and go on to infecting other cells leading to massive cell destruction and ultimately death in nearly 80% of the cases. The review found that the progression of Ebola virus infection is very similar to that of Influenza A virus, the causative agent that was responsible for the death of over 90 million people in the 1918 flu pandemic. In severe Influenza A virus infections, a condition associated with high mortality rate called haemophagocytic lymphohistiocytosis (HLH) is developed by the affected patient. HLH has previously been treated successfully with Etoposide which increased survivability from 50% to 90% (LANCET, Volume 367, Pages 870-873, March 2006). Etoposide is an anticancer drug that inhibits the activity Topoisomerase II, an essential enzyme found in hyperactive, rapidly growing cells such as cancer cells and HLH cells. Like Etoposide, Sunshine Biopharma's lead anticancer compound, Adva-27a, is a Topoisomerase II inhibitor however it has been shown to be more effective and less toxic than Etoposide (ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). The latter characteristics make Adva-27a superior to Etoposide for possible treatment of Ebola patients with already weakened state of health.
Sunshine Biopharma Retains Renmark Financial Communications to Provide Investor Relations
Marketwired - Tue Oct 14, 7:06AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, including its proprietary lead anticancer compound Adva-27a, today announced that it has retained the services of Renmark Financial Communications Inc. to handle its investor relations activities.
Sunshine Biopharma's Wholly Owned Canadian Subsidiary Completes the SOP's Required by Health Canada to Secure Drug Establishment License
Marketwire - Wed Oct 01, 7:02AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that its wholly owned Canadian subsidiary has completed the drafting of all of the Standard Operating Procedures (SOP's) required by Health Canada for the procurement of a Drug Establishment License (DEL). The completed SOP's comprise 18 binders and over 2,000 pages of documentation. It is necessary for Sunshine to have the DEL in place in order to become a fully integrated pharmaceutical company with proprietary (Adva-27a) and generic pharmaceutical products offering.
Sunshine Biopharma Negotiating With CRO's to Initiate Master Drug File for Adva-27a Anticancer Compound
Marketwire - Wed Sep 03, 7:03AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it is currently negotiating with several Contract Research Organizations (CRO's) with the intent to engage one of them for the purposes of initiating, compiling and managing a regulatory master drug file for Adva-27a, the Company's flagship anticancer compound. A master drug file contains all of the information that regulatory agencies require as part of the drug development and approval process. Such information includes preclinical data, GMP manufacturing process, large animal studies and human trials.
Sunshine Biopharma's Wholly Owned Canadian Subsidiary Engages Health Canada Specialized Consultants to Secure Pharmaceutical Establishment License
ACCESSWIRE - Thu Aug 21, 7:01AM CDT
Montreal, Quebec, Canada / ACCESSWIRE / August 21, 2014 / Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that its wholly owned Canadian subsidiary has engaged consultants specialized in Health Canada procedures and requirements to prepare the necessary documentations and applications for the procurement of a Pharmaceutical Establishment License. Such licensing must be in place before the Company is able to sign manufacturing and distribution contracts and accept purchase orders for the sale of pharmaceutical products.
Sunshine Biopharma's Wholly Owned Canadian Subsidiary Secures Dedicated Space to Commence Global Generic Pharmaceutical Operations
Marketwire - Mon Aug 11, 7:03AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that its wholly owned Canadian subsidiary has secured dedicated space in order to commence operations in the generic pharmaceuticals business as planned. Having a specifically dedicated space is required in order for the Company to be granted a Pharmaceutical Establishment and Export License by Health Canada. Once we secure our Establishment Licensed we will be in a position to sign manufacturing and distribution contracts for sale of generic pharmaceuticals in Canada and elsewhere around the globe. According to various estimates, the annual worldwide market for generic pharmaceuticals which Sunshine Biopharma's Canadian subsidiary is positioning itself to participate in is in excess of $100 billion.
Sunshine Biopharma Launches Sunshine Biopharma Canada Inc., a Wholly Owned Canadian Subsidiary in Anticipation of Signing Manufacturing and Commercialization Contracts in Canada
Marketwire - Tue Jul 29, 7:03AM CDT
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has formed Sunshine Biopharma Canada Inc., a Canadian wholly owned subsidiary for the purposes of conducting pharmaceutical business in Canada and elsewhere around the globe. Sunshine Biopharma anticipates that Sunshine Biopharma Canada will soon sign manufacturing, marketing, sales and distribution contracts for various pharmaceutical and biomedical products. According to various estimates, the worldwide market for generic pharmaceuticals which Sunshine Biopharma Canada is positioning itself to participate in is in excess of $100 billion per year.
Jang Attributes Peaceful Council Elections to Security Arrangements
by Seriki Adinoyi - All Africa Global Media - Wed Feb 26, 1:34AM CST
Governor Jonah Jang of Plateau State has attributed the peaceful conduct of the local government area elections in the state to the adequate security measures put in place for the exercise.
